Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Volker Ellenrieder

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9981-8571; OpenAlex author ID A5046422102. Sources: OpenAlex.

Their work

Papers
50 (first author 3, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
143
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 2 papers · 2024: 7 papers · 2025: 4 papers · 2026: 6 papers

Papers 50

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  3. GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Last author DOI 10.1136/gutjnl-2025-336227↗
  4. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  5. High-Dimensional Immunophenotyping of Plasma-Derived Small Extracellular Vesicles in Pancreatic Cancer: An Exploratory Proof-of-Principle Study. Co-author DOI 10.3390/biom16070942↗
  6. Benchmarking the Intratumoral Microbiome in Pancreatic Ductal Adenocarcinoma: A Longitudinal Assessment of Contamination Sources and Decontamination Strategies Co-author DOI 10.64898/2026.08.24.746744↗
  7. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  8. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Co-author DOI 10.1038/s41467-024-55330-7↗
  9. TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Co-author DOI 10.1126/sciadv.adu2339↗
  10. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334374↗
  11. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  12. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing. Co-author DOI 10.1016/j.neo.2024.101002↗
  13. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  14. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  15. A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer. Co-author DOI 10.1093/nargab/lqae057↗
  16. A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys. Co-author DOI 10.3233/shti240862↗
  17. Prolonged survival by combination treatment with a standardized herbal extract from Japanese Kampo-medicine (Juzentaihoto) and gemcitabine in an orthotopic tra… Co-author DOI 10.3389/fonc.2024.1454291↗
  18. Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.07.008↗
  19. Neutrophil-derived complement factor P induces cytotoxicity in basal-like cells via caspase 3/7 activation in pancreatic cancer Co-author DOI 10.1101/2023.10.28.564512↗
  20. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling? First author DOI 10.1159/000521847↗
  21. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. Co-author DOI 10.1172/jci.insight.154475↗
  22. TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers14143451↗
  23. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Co-author DOI 10.1038/s43018-021-00258-w↗
  24. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  25. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2874↗
  26. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Co-author DOI 10.3390/cells10123463↗
  27. Microenvironmental Determinants of Pancreatic Cancer. Co-author DOI 10.1152/physrev.00042.2019↗
  28. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗
  29. [New milestone in adjuvant therapy for pancreatic cancer]. First author DOI 10.1007/s00108-019-0628-1↗
  30. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  31. Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression. Co-author DOI 10.1038/s41419-019-1682-2↗
  32. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Co-author DOI 10.3390/cells8060563↗
  33. Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer. Co-author DOI 10.3390/cells9010058↗
  34. Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models. Co-author DOI 10.3791/56979↗
  35. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Last author DOI 10.1136/gutjnl-2016-312539↗
  36. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Co-author DOI 10.1038/onc.2015.216↗
  37. NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. Co-author DOI 10.1155/2016/5272498↗
  38. GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/1535-7163.mct-15-0309↗
  39. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1159/000447739↗
  40. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  41. [Pancreatic cancer stroma: oncologist's ally or foe?]. First author DOI 10.1055/s-0034-1398955↗
  42. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Last author DOI 10.15252/embj.201489574↗
  43. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Co-author DOI 10.1038/cddis.2014.102↗
  44. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells Co-author DOI 10.1038/cddis.2014.341↗
  45. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Last author DOI 10.1055/s-0034-1366002↗
  46. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Last author DOI 10.1158/2159-8290.cd-13-0593↗
  47. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Co-author DOI 10.1593/neo.121312↗
  48. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Last author DOI 10.1053/j.gastro.2011.11.001↗
  49. Transcriptional control of gene expression in pancreatic cancer: from sequence-specific transcription factors to nuclear architecture. Co-author DOI 10.1007/s12029-011-9254-4↗
  50. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. Last author DOI 10.1074/jbc.m110.197533↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisabeth Heßmann · 33 shared papers, 2014–2026 · strength 4.25
  2. Albrecht Neeße · 19 shared papers, 2014–2026 · strength 2.18
  3. Shiv K. Singh · 19 shared papers, 2011–2026 · strength 2.12
  4. Günter Schneider · 8 shared papers, 2016–2026 · strength 1.22
  5. Steven A. Johnsen · 9 shared papers, 2017–2026 · strength 1.11
  6. Matthias Wirth · 7 shared papers, 2015–2026 · strength 1.08
  7. Lukas Klein · 7 shared papers, 2019–2026 · strength 1.07
  8. Christoph Ammer‐Herrmenau · 5 shared papers, 2023–2026 · strength 1.06
  9. Maximilian Reichert · 6 shared papers, 2021–2026 · strength 0.93
  10. Michael B. Ghadimi · 5 shared papers, 2024–2026 · strength 0.93
  11. Ulrich Sax · 5 shared papers, 2024–2026 · strength 0.92
  12. Alexander Otto König · 11 shared papers, 2011–2024 · strength 0.86
  13. Carolin Schneider · 5 shared papers, 2024–2026 · strength 0.84
  14. Dieter Saur · 5 shared papers, 2021–2026 · strength 0.80
  15. Jochen Gaedcke · 7 shared papers, 2015–2025 · strength 0.79
  16. Laura Urbach · 5 shared papers, 2020–2025 · strength 0.73
  17. Jens Thomas Siveke · 8 shared papers, 2014–2026 · strength 0.71
  18. Marian Grade · 4 shared papers, 2024–2026 · strength 0.71
  19. Lukas Krauß · 4 shared papers, 2024–2026 · strength 0.71
  20. Roland Michael Schmid · 5 shared papers, 2015–2026 · strength 0.65
  21. Stephan A. Hahn · 5 shared papers, 2015–2026 · strength 0.61
  22. Shilpa Patil · 6 shared papers, 2018–2022 · strength 0.60
  23. Lena‐Christin Conradi · 3 shared papers, 2025–2026 · strength 0.58
  24. Uday Kishore · 4 shared papers, 2021–2025 · strength 0.55
  25. Mengyu Tu · 4 shared papers, 2021–2025 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.